Drug resistance-associated markers P-glycoprotein, multidrug resistance- associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2798-2805

  Arts, Henriette J G ^a   Katsaros, Dionyssios ^d   De Vries, Elisabeth G E ^a   Massobrio, Marco ^d   Genta, Franco ^d   Danese, Silvio ^d   Arisio, Riccardo ^d   Scheper, Rick J ^b   Kool, Marcel ^c   Scheffer, George L ^b   Willemse, Pax H B ^a   Van Der Zee, Ate G J ^a   Suurmeijer, Albert J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROGNOSIS; SURVIVAL RATE; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0032740801     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kugera, P. R., Partridge, E. E., Look, K. Y. Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
3. Kristensen, G. B., and Trope, C. Epithelial ovarian carcinoma. Lancet, 349: 113-117, 1997.
4. Ozols, R. F., and Vermorken, J. B. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin. Oncol., 24: S2-1-S2-9, 1997.
5. Dunton, C. J. New options for the treatment of advanced ovarian cancer. Semin. Oncol., 24: S5-2-S5-11, 1997.
6. Johnson, S. W., Ozols, R. F., and Hamilton, T. C. Mechanisms of drug resistance in ovarian cancer. Cancer (Phila.), 71: 644-649, 1993.
7. Van der Zee, A. G. J., Hollema, H. H., de Bruijn, H. W., Willemse, P. H. B., Boonstra, H., Mulder, N. H., Aalders, J. G., and de Vries, E. G. E. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol. Oncol., 58: 165-178, 1995.
8. Lehnert, M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer, 32A: 912-191, 1996.
9. Loe, D. W., Deeley, R. G., and Cole, S. P. C. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer, 32A: 945-957, 1996.
10. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
11. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., and Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129, 1996.
12. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J. T., Juijn, J. A., Baas, F., and Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res., 57: 3537-3547, 1997.
13. Keppler, D., Leier, I., and Jedlitschky, G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. J. Biol. Chem., 378: 787-791, 1997.
14. Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S., Ono, M., and Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res., 57: 5475-5479, 1997.
15. Evers R., Kool M., van Deemter, L., Janssen, H., Calafat, J., Oomen, L. C., Paulusma, C. C., Oude Elferink, R. P., Baas, F., Schinkel, A. H., and Borst, P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Investig., 101: 1310-1319, 1998.
16. Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R., and Scheper, R. J. Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int. J. Cancer, 65: 230-237, 1996.
17. Scheffer, G. L., Wijngaard, P. L., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J., Clevers, H. C., and Scheper, R. J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med., 6: 578-582, 1995.
18. Izquierdo, M. A., van der Zee, A. G. J., Vermorken, J. B., van der Valk, P., Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., Meijer, C. J. L. M., de Vries, E. G. E., and Scheper, R. J. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87: 1230-1237, 1995.
19. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for cancer of the cervix and ovary. Am. J. Obstet. Gynecol., 156: 236-241, 1987.
20. Rubin, S. C. (ed.). Chemotherapy of Gynecologic Cancer, Society of Gynecologic Oncologists Handbook, p. 187. New York: Lippincott-Raven, 1996.
21. Serov, S. F., Scully, R. E., and Sobin, L. H. Histological typing of ovarian tumors, pp., 17-18. Geneva: WHO, 1973.
22. Sobre, B., Frankendal, B., and Veress, B. Importance of histological grade in the prognosis of epithelial ovarian carcinomas. Obstet. Gynecol., 59: 567-573, 1982.
23. Scheper, R. J., Bulte, J. W., Brakkee, J. G., Quak, J. J., van der Schoot, E., Balm, A. J., Meijer, C. J., Broxterman, H. F., Kuiper, C. M., and Lankelma, J. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int. J. Cancer, 42: 389-394, 1988.
24. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J., and Zaman, G. J. R. Immunochemical detection of the multidrug resistance-associated MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
25. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.
26. Paulusma, C. C., Bosnia, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., and Oude Elferink, R. P. J. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Washington DC), 271: 1126-1128, 1996.
27. Van der Zee, A. G. J., Hollema, H. H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H. B., Aalders, J. G., and de Vries, E. G. E. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol., 13: 70-78, 1995.
28. Alberts, D. S., Taetle, R., Frutiger, E., Heddens, D., Laptalo, L., Einspahr, J., Gilmore, D., and Grogen, T. Multidrug resistance expression as an independent risk factor for poor survival in optimal stage III ovarian cancer. Proc. Am. Soc. Clin. Oncol., 17: 347, 1998.
29. Rubin, S. C., Finstad, C. L., Hoskins, W. J., Saigo, P. E., Provencher, D. M., Federici, M. G., Hakes, T. B., Markman, M., Reichman, B. S., Lloyd, K. O., and Lewis, J. L. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am. J. Obstet. Gynecol., 163: 69-73, 1990.
30. Van der Zee, A. G., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G., and de Vries, E. G. E. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res., 57: 5915-5920, 1991.
31. Arao, S., Suwa, H., Mandai, M., Tashiro, H., Miyazaki, K., Okamura, H., Nomura, H., Hiai, H., and Fukumoto, M. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res., 54: 1355-1359, 1994.
32. Broxterman, H. J., Lankelma, J., and Pinedo, H. M. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur. J. Cancer, 32A: 1024-1033, 1996.
33. Kavallaris, M., Leary, J. A., Barrett, J. A., and Friedlander, M. L. MDRI and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett., 702: 7-16, 1996.
34. Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems, E. W. H. M., de Haas, M., Smith, A. J., Broxterman, H. F., Mulder, N. H., de Vries, E. G. E., Baas, F., and Borst, P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 55: 1747-1750, 1993.
35. Barrand, M. A., Heppellparton, A. C., Wright, K. A., Rabbitts, P. H., and Twentyman, P. R. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J. Natl. Cancer Inst., 86: 110-117, 1994.
36. Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J. R., Scheper, R. J., van Wingerdern, K. E., Burger, H., Oostrum, R., Boersma, T., Sonneveld, P., Gratama, J. W., Kok, T., Eggermont, A. M. M., Bosnian, F. T., and Stoter, G. Expression of the multidrug resistance associated protein (MRP) gene in human cancers. Clin. Cancer Res., I: 1301-1010, 1995.
37. Borst, P., Kool, M., and Evers, R. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin. Cancer Biol., 8: 205-213, 1997.
38. Kauffmann, H. M., Keppler, D., Kartenbeck, J., and Schrenk, D. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology, 26: 980-985, 1997.
39. Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., and Giaccone, G. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer, 71: 787-795, 1997.
40. Filipits, M., Pohl, G., Stranzl, T., Suchomel, R. W., Scheper, R. J., Jager, U., Geissler, K., Lechner, K., and Pirker, R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91: 1508-1513, 1998.
41. Raaijmakers, H. G., Izquierdo, M. A., Lokhorst, H. M., de Leeuw, C., Belien, J. A., Bloem, A. C., Dekker, A. W., Scheper, R. J., and Sonneveld, P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, 91: 1029-1036, 1998.
42. List, A. F., Spier, C. S., Grogan, T. M., Johnson, C., Roe, D. J., Greer, J. P., Wolff, S. N., Broxterman, H. J., Scheffer, G. L., Scheper, R. J., and Dalton, W. S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87: 2464-2469, 1996.
43. Volm, M., Stammler, G., Zintl, F., Koomagi, R., and Sauerbrey, A. Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anticancer Drugs, 8: 662-665, 1997.